Aaron Green, Chief Executive Officer of OneMedNet Corp (NASDAQ:ONMD), has executed a series of direct purchases of the company's common stock, accumulating a total value of $30,696. These transactions took place over a four-day window from June 12 to June 15, 2026. The acquisition prices varied between $0.5396 and $0.5581 per share, reflecting a strategic entry point during a period of market volatility.
According to official filings submitted to the U.S. Securities and Exchange Commission, the initial transaction occurred on June 12, 2026. During this date, Mr. Green acquired 36,920 shares at a weighted average price of $0.5581 per share. The execution of this purchase involved multiple transactions, with individual share prices ranging from $0.5463 to $0.5625. This substantial acquisition was followed by a second transaction on June 15, 2026, where Mr. Green purchased an additional 18,702 shares at a price of $0.5396 per share. Following these recent acquisitions, Mr. Green's direct ownership in OneMedNet Corp has increased to 1,859,725 shares of common stock.
The timing of these insider purchases is notable given the recent performance of the stock. Over the past week, the share price has declined by approximately 14%, with shares currently trading at $0.56. According to analysis from InvestingPro, the company's market capitalization is currently valued at $30.37 million. InvestingPro provides additional exclusive insights and comprehensive financial metrics for subscribers interested in ONMD.
Despite the recent stock decline, OneMedNet has reported significant financial improvements. For the year 2025, the company recorded a 329% increase in revenue, reaching $1.25 million compared to $292,000 in 2024. Additionally, the company reduced its liabilities by 74%, decreasing from $19.7 million to $5.1 million. The shareholder deficit also improved substantially, moving from $(16.0) million to $(3.0) million. Looking ahead, OneMedNet has secured over $3 million in bookings for 2026, already surpassing its total bookings for 2025. These bookings are expected to be recognized as revenue by the end of the third quarter of 2026.
However, the company faces regulatory challenges. OneMedNet received a notice from the Nasdaq Listing Qualifications Department regarding non-compliance with the $1.00 minimum bid price requirement for continued listing. The company has until October 12, 2026, to regain compliance with this requirement. In other developments, OneMedNet announced a partnership with Inka Health, a subsidiary of Onco-Innovations Limited. This collaboration will provide access to OneMedNet's iRWD platform for U.S. real-world oncology data, supporting the development of Onco-Innovations' PNKP Inhibitor Technology.
Market data indicates that OneMedNet's stock closed at $0.558 on June 15, representing a gain of $0.0145 or 2.67%. Pre-market trading showed a slight decline of $0.0002 or 0.04% at $0.5578. The stock's performance over various time frames, including 1 day, 1 week, 1 month, 6 months, 1 year, 5 years, and maximum history, highlights the volatility and recent trends in investor sentiment.
Investors are encouraged to review strategies and analyze ONMD to understand the implications of these developments. The combination of strong financial growth, strategic partnerships, and regulatory challenges presents a complex landscape for stakeholders.